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Background: Adults with end-stage renal disease treated with dialysis experience a high burden of foot ulceration
and lower extremity amputation. However, the risk factors for foot ulceration in the dialysis population are
incompletely understood due to the lack of high-quality prospective evidence. This article outlines the design of a
prospective observational cohort study, which aims to investigate the risk factors for foot ulceration in adults on
dialysis.
Methods/Design: This study will recruit 430 participants with end-stage renal disease on dialysis from satellite and
home-therapy dialysis units across multiple health organisations in Melbourne, Victoria, Australia. Data collection at
baseline will include a participant interview, medical record review, completion of a health-status questionnaire and
a non-invasive foot assessment. Twenty participants will also be recruited to a reliability study to evaluate the
reproducibility of testing procedures. Primary outcome data includes: new foot ulcer(s). Secondary outcome data
includes: number of new foot ulcers, time to onset of new foot ulcer(s), new lower extremity amputation(s), episodes
of infection of the foot or lower extremity, episodes of osteomyelitis, foot-related hospitalisations, revascularisation
procedure(s) of the lower extremity, new podiatry interventions, kidney transplantation, and mortality. Participants will
be assessed at baseline, and at 12 months they will be evaluated for the primary and secondary outcomes. Multivariate
Cox proportional hazards models will be used to assess predictors of new foot ulceration and time to event secondary
outcomes. Logistic regression will be used for binary outcomes including prevalence of foot ulcerations.
Discussion: This is the first multi-centre prospective observational cohort study to investigate risk factors for foot
ulceration in adults with end-stage renal disease on dialysis. This study will improve on prior studies by using
prospective methods, multi-centre recruitment, statistical methods to control for confounding variables, and a
pre-specified sample size estimation. The findings can inform the design of future trials evaluating the
effectiveness of clinical interventions, which may lead to improved patient outcomes in the dialysis setting.
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End-stage renal disease (ESRD) is a global public health
problem characterised by a significant loss in kidney func-
tion, causing retention of metabolic waste products, salt
and fluid in the body [1]. The accumulation of these waste
products can become fatal unless renal replacement ther-
apy (i.e. dialysis or kidney transplantation) is sought. It is* Correspondence: mrkaminski@students.latrobe.edu.au
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ESRD incidence rate increasing at an annual growth rate
of 8 % [3].
Adults with ESRD on dialysis are at high risk for foot
ulceration and subsequent lower extremity amputation
[4–12]. This risk is similar to those with diabetes [5, 12,
13]. Not surprisingly, individuals who are both diabetic
and dialysis-dependent have even higher rates of foot ul-
ceration and amputation [5, 14]. Foot ulceration is a major
public health concern and can have a detrimental impact
on an individual’s general health, functional status andle is distributed under the terms of the Creative Commons Attribution 4.0
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progress to other serious lower extremity complications
such as deep infections, and result in subsequent hospital-
isation, limb loss, and foot-related mortality [5, 7, 18, 19].
In addition, the treatment and management of foot ulcers
generates a considerable financial burden with increased
demand on health care systems [20–22]. For example, a
recent study [23] conducted in the United States reported
the annual cost of diabetic foot ulceration on public and
private payers is between US$9 - $13 billion, not including
the costs associated with diabetes management itself.
The incidence of foot ulceration in the dialysis popula-
tion is currently uncertain. However, a recent retrospect-
ive study by Lavery et al. [14] estimated a cumulative foot
ulceration incidence rate of 210 per 1000 person-years in
dialysis patients with coexisting diabetes. The central de-
terminants for the development of foot ulcers in the dialy-
sis setting are poorly understood, although meta-analyses
performed in our recent systematic review found that pos-
sible risk factors include: previous foot ulceration or lower
extremity amputation, peripheral arterial disease, coronary
artery disease, diabetes mellitus (increasing with longer
duration of disease), peripheral neuropathy, retinopathy,
lower serum albumin levels and higher serum phosphorus
levels [24].
Risk factors reported in the literature are frequently
based on associations identified in retrospective or cross-
sectional studies. To our knowledge, there are no ad-
equately powered multi-centre prospective cohort studies
that have investigated risk factors for foot ulceration in
the dialysis population. Prospective studies are essential to
gain greater control over data collection methods and pro-
vide a temporal sequence of events; that is, whether a vari-
able is associated with an increase in the condition of
interest [25].
With the above in mind, the aim of this article is to
describe the design of a multi-centre prospective obser-
vational cohort study that will investigate risk factors for
foot ulceration in adults with ESRD on dialysis.
Methods/Design
Ethical approval
The Human Research and Ethics Committees of La Trobe
University, Eastern Health, Austin Health, and Monash
Health (reference numbers: FHEC13/213, LR14/1314, LN
R/14/Austin/97 and 14419X, respectively) have approved
the study and all participants will provide written in-
formed consent prior to enrolment and data collection.
Study design
The design is a multi-centre prospective observational
cohort study with a 12 month follow-up period. Initially,
we performed a systematic synthesis of existing litera-
ture to quantify the major risk factors for foot ulcerationand amputation in adults with ESRD treated with dialy-
sis [24]. Our decision on which risk factors to include in
this prospective observational cohort study is based not
only on our systematic review findings [24], but is also
informed by a comprehensive review of the diabetes lit-
erature. A 12-month follow-up period was chosen as it
will provide an adequate time frame for the development
of new foot ulceration [26, 27].
Data collection will consist of two appointments; a
baseline appointment and a follow-up appointment. One
examiner (M.R.K.) will conduct the baseline and follow-
up appointments on all participants. Figure 1 outlines
the study design. Data to be collected at baseline will be
obtained from an interview with the participant, medical
record review, completion of a health-status question-
naire and a non-invasive foot assessment. A comprehen-
sive literature review was performed to determine the
most valid and reliable tools to measure suspected risk
factors, for use in the foot assessment. The data collec-
tion form for the baseline data is available in Additional
file 1. In addition, twenty participants will also be re-
cruited to a reliability study to assess the repeatability
of the foot assessment tools. These participants will be
screened for suspected risk factors for foot ulceration on
two separate occasions by the same examiner (M.R.K.),
with each assessment spaced one week apart. The foot as-
sessments to be repeated on the twenty participants in the
reliability study (i.e. one week later) includes: protective
sensation with the Baily Instruments Ltd® (Salford Quays,
UK) Semmes-Weinstein 5.07/10 g Monofilament, vibra-
tion perception threshold with the Horwell® (Wilford,
Nottingham, UK) Neurothesiometer, toe-brachial pressure
index with the SysToe® (Atys Medical, Soucieu-en-
Jarrest, France) system, ankle-brachial index using the
Doppler ultrasound technique and first metatarsopha-
langeal joint range of motion with a goniometer. One
examiner (M.R.K.) will perform all of the foot assess-
ments on the participants, thus ensuring consistency
and accuracy in the measurements, and reducing the
chance of systematic error.
Primary and secondary outcome data will be col-
lected at the 12 month follow-up appointment. The
data collection form for the prospective data (i.e. 12-
month follow-up) is available in Additional file 2.
Primary outcome data includes: new foot ulcer(s)
(including new and reoccurring ulcers). Secondary
outcome data includes: number of new foot ulcers,
time to onset of new foot ulcer(s), new lower extrem-
ity amputation(s) (including level of amputation and
reason for amputation), episodes of infection of the
foot or lower extremity (including type of infection),
episodes of osteomyelitis, foot-related hospitalisations
(including reason for admission, length of stay, and
foot-related treatments/procedures received during
Fig. 1 Design of study
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the lower extremity (including type of revascularisa-
tion procedure), new podiatry interventions (e.g. nail/
callus reduction, prescription of foot orthoses), kidney
transplantation, and mortality (including primary and
secondary causes of death).
Participant recruitment, screening and eligibility criteria
Participants will be recruited from satellite dialysis
units (i.e. centres where patients attend for dialysis
treatment) and home-therapy dialysis units (i.e. dialysis
treatment is performed at home) throughout Eastern
Health, Austin Health and Monash Health in Mel-
bourne, Victoria, Australia. Recruitment and collectionof baseline data is anticipated to occur between January
2014 and December 2014.
Prospective participants will be identified by liaising
with the renal dialysis nurses in the satellite and home-
therapy dialysis units, according to the study eligibility
criteria. Those attending the satellite dialysis units will be
screened face-to-face, whereas respondents to the mail-
out (i.e. home-therapy participants) will be screened for
eligibility via telephone.
Patients attending for dialysis in the satellite units will
be approached by the chief investigator (M.R.K.) during
their dialysis treatment. If interested, they will be offered
verbal and written information about the project and
will have the opportunity to join the study at the time of
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telephone call. Alternatively, prospective participants
may contact the research team at their own convenience
if they are interested in participating.
Patients in the home-therapy dialysis program will be
mailed a covering letter and an information package,
along with an invitation to contact the research team by
telephone or email if they are interested in participating.
Patient lists from the home-therapy dialysis unit will be
screened prior to mailing to confirm that addresses are
current and to exclude any recent deaths or discharges.
To be included in the study, participants will be eli-
gible if they:
(i) have ESRD and are clinically stable on dialysis
(haemodialysis or peritoneal dialysis);
(ii) are at least 18 years of age and;
(iii) are cognitively aware (i.e. they can provide
informed consent).
Participants will be excluded if they:
(i) have insufficient English skills to provide informed
consent or follow instructions during the project
and;
(ii) are unwilling to give informed consent to
participate.
Participants’ cognition and English language proficiency
(to provide informed consent or follow instructions during
the project) will be confirmed by the chief investigator
(M.R.K.) in collaboration with the nursing staff in the dia-
lysis units. To determine this, prospective recruits’ under-
standing of what participation in the study involves will be
ascertained prior to signing informed consent.
Baseline appointment
Data will be collected at the baseline appointment via an
interview with the participant and by reviewing medical
records and routine blood test results. Baseline variables
or factors relating to participant characteristics, comor-
bidities and laboratory blood test results (Table 1) were
selected based on the findings of our systematic review
[24] and from a comprehensive review of the diabetes
literature. An average of the three latest blood test re-
sults (i.e. C-reactive protein, serum albumin, total cal-
cium, serum phosphate, parathyroid hormone, glycated
haemoglobin and haemoglobin) will be obtained at base-
line for the purposes of statistical analysis.
Previous studies have demonstrated that health-
related quality of life is negatively impacted by the pres-
ence of a diabetic foot ulcer [28, 29]. Generic health
status will be assessed with the short-form 36 version
2.0 health survey (SF-36v2®). The SF-36v2® has beenextensively validated (construct, concurrent, content,
criterion and predictive validity) and provides a reliable
measure of physical and mental health in a range of popu-
lations [30–33]. The SF-36v2® is a 36 question survey that
covers eight health domains that are summarised under
two components, (i) a physical component summary in-
cluding: physical functioning, role-physical, bodily pain
and general health, and (ii) a mental component summary
including: vitality, social functioning, role-emotional and
mental health [34].
A non-invasive foot assessment will screen for the
suspected risk factors for foot ulceration. Neurological
(Table 2), arterial (Table 3), biomechanical (Table 4),
footwear (Table 5) and dermatological (Table 6) assess-
ments will be conducted. Data will also be collected on
previous history of lower extremity complications (Table 7)
and foot health care behaviours, including podiatry at-
tendance (Table 8).
Neurological assessment
The presence of peripheral neuropathy will be assessed
using a Baily Instruments Ltd® (Salford Quays, UK)
Semmes-Weinstein 5.07/10 g Monofilament and a Horwell®
(Wilford, Nottingham, UK) Neurothesiometer, based
on the recommendations of the American Diabetes
Association [35]. These tests will evaluate loss of pro-
tective sensation and vibration perception threshold,
respectively.
A recent systematic review reported that a failed
Semmes-Weinstein monofilament test is a significant
and independent predictor for subsequent foot ulcer-
ation in patients with diabetes [36]. A systematic re-
view of validation studies found that testing of loss of
protective sensation with a 10 g monofilament has
reported sensitivity of 57 to 93 % and specificity of
75 to 100 % for detecting diabetic neuropathy [36].
The Baily Instruments Ltd® monofilament was selected
for use in this study as it is one of the most accurate
monofilaments to produce a 10 g buckling force (100 %
buckling within ±1.0 g of 10 g) [37]. The plantar as-
pects of the hallux, first and fifth metatarsals will be
assessed [38, 39].
The vibration perception threshold will be evaluated
as it can identify those with less severe forms of neur-
opathy (i.e. before loss of protective sensation is evident
clinically) [40]. A review of validation studies found that
testing of vibration perception threshold with either a
Neurothesiometer or Biothesiometer has reported sensi-
tivity (77 to 100 %) and specificity (73 to 81 %) ranges for
detecting diabetic neuropathy [40]. A vibration percep-
tion threshold of >25 V (tested on the apex of the hal-
lux) in at least one foot will be used as the cut off value
in this study, as it has been associated with a high cu-
mulative risk of neuropathic ulceration [41, 42].
Table 1 Baseline data: participant characteristics, comorbidities and laboratory blood test results
Participants characteristics Comorbidities Laboratory blood
test results
Age (years) Diabetes (documented diagnosis in medical history, including type and duration) C-reactive protein
(mg/L)
Sex (male or female) Retinopathy (documented diagnosis in medical history) Serum albumin
(g/dL)
Height (m) Known peripheral neuropathy (documented diagnosis in medical history) Total calcium
(mmol/L)
Weight (kg) Known peripheral arterial disease or history of lower extremity revascularisation
procedure (documented diagnosis in medical history or documented lower extremity








Body mass index (kg/m2) Hypertension (documented diagnosis in medical history and must be requiring
medication)
Smoking history (past, current, never) Dyslipidaemia (documented diagnosis in medical history)
Living arrangements (living alone) Ischaemic heart disease (documented diagnosis of ischaemic heart disease, angina,
myocardial infarction or coronary bypass surgery in medical history)
Ethnicity
• Indigenous Australian (Aboriginal or
Torres Strait Islander)
• English Congestive cardiac failure (documented diagnosis in medical history)
• European
• American
• African Cerebrovascular disease (documented diagnosis of cerebrovascular accident




Cause of end-stage renal disease
• Diabetic nephropathy Osteoarthritis (documented diagnosis in medical history)
• Hypertensive nephropathy
• Chronic glomerulonephritis Inflammatory arthritis (documented diagnosis in medical history of a type of
inflammatory arthritis e.g. gout, rheumatoid arthritis, psoriatic arthropathy)








• Continuous ambulatory peritoneal
dialysis
• Automated peritoneal dialysis
Duration of dialysis (months)
An average of the three latest blood test results (i.e. C-reactive protein, serum albumin, total calcium, serum phosphate, parathyroid hormone, glycated
haemoglobin and haemoglobin) will be obtained at baseline
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Table 2 Baseline data: neurological assessment
Neurological
assessments









Baily Instruments Ltd® (Salford
Quays, UK) Semmes-Weinstein
5.07/10 g monofilament [37].
• Monofilament is first applied to participant’s
hand or elbow (so that the participant knows
what sensation to expect)
Failure to detect the monofilament at a specific
site, even after re-testing the deficit site, in at
least one foot will result in a failed test (i.e. score
of <3/3 on either foot) [36].
• Ensure the participant’s eyes are closed
• Monofilament applied perpendicular to the skin
and held for 1–2 secs, applying sufficient force
to bend or buckle the monofilament fibre [16]
• Monofilament applied to the plantar aspects of
the hallux, first metatarsophalangeal joint and fifth
metatarsophalangeal joint of both feet [36, 43]
• Participant is asked by the assessor to respond
“yes” when they feel the monofilament
• This is repeated for all 3 sites on each foot (6
sites in total)
• Deficit sites will be re-tested once
• A monofilament will be not be used on more
than 10 participants, without a recovery period






• Neurothesiometer is first applied to the
participant’s hand or elbow (so that the
participant knows what sensation to expect)
Vibration perception threshold >25 V in at least
one foot will result in a failed test [40–43].
• Participant is asked to close their eyes and to
report “yes” when they first start to feel a
vibratory sensation
• Neurothesiometer is applied to the apex of the
hallux and the voltage is gradually increased
until the participant perceives the vibratory
sensation [40, 43]
• The minimum reading at which the vibratory
sensation is perceived will be recorded (this is
repeated 3 times and an average score is
recorded for both feet) [40, 43]
Note: Vibration perception threshold will be
measured at the base of the first, third or fifth
metatarsals if there are current ulcers on the
hallux, or previous amputation of the hallux [43].
N/A Not applicable
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following are present:
 Documentation of known peripheral neuropathy in
the medical records;
 Monofilament score of <3/3 (either foot) [36];
 Vibration perception threshold >25 V (either foot)
[40–43].
Arterial assessment
The presence of peripheral arterial disease will be
assessed by palpating pedal pulses (i.e. dorsalis pedis
and posterior tibial) and by calculating the toe-brachial
pressure index and the ankle-brachial pressure indexbilaterally. Symptoms for peripheral arterial disease (i.e.
intermittent claudication and rest pain) will not be
assessed in this study, as it is likely that there is a high
prevalence of asymptomatic peripheral arterial disease
in this population, due to a high co-prevalence of dia-
betes, infections and neuropathy [44]. A combination of
the toe-brachial pressure index and ankle-brachial pres-
sure index measurements will allow for a more accurate
representation of the prevalence of peripheral arterial dis-
ease, due to the known high prevalence rates of medial
arterial calcification in dialysis patients [45, 46].
As per the recommendations of Leskinen et al. [45], toe-
brachial pressure indices ≤0.6 and/or ankle-brachial pres-
sure indices ≤0.9 will indicate the presence of peripheral
Table 3 Baseline data: arterial assessment
Arterial assessments Equipment Procedure Diagnosis/study definition
Known peripheral arterial
disease and/or history of
lower extremity
revascularisation procedure
N/A Medical record review. History of peripheral arterial disease and/or lower
extremity revascularisation procedure documented
in medical records.
Pedal pulses N/A • Physical palpation of the dorsalis pedis and
posterior tibial pulses on both feet with the
examiners fingers (4 pulses in total) [52]
Absence of ≥2 pedal pulses will indicate
peripheral arterial disease [52].







• Toe pressure measurement will be
performed prior to the ankle pressure
measurement to ensure arterial supply to
the toes is not affected
Toe-brachial pressure index ≤0.6 will indicate
peripheral arterial disease [44, 45, 53].
• Room temperature (minimum 21–23 ± 1°
C) to prevent vasoconstriction of digital
arteries [92]
• Participants will be rested for a minimum
of 15 min prior to assessment
• Participants to avoid use of tobacco and
consumption of coffee for at least one
hour prior to assessment [92, 93]
• Pneumatic cuff (120 x 25 mm) is placed
on the proximal phalanx of hallux
(i.e. proximal cuff) [47, 48]
Note: If hallux is absent, a 90 x 15 mm
digital cuff will be used on the second toe
[48, 49].
• Double-sided tape is applied to sensor [47]
• Sensor is positioned on the plantar aspect
of the hallux (or second toe) and secured
with another pneumatic cuff (i.e. distal
cuff) [47, 48]
• Turning the SysToe® device on will cause
an automated sequence involving inflation
of the distal cuff, then inflation of the
proximal cuff, followed by rapid deflation
of the distal cuff and slower deflation of
the proximal cuff (3 mm Hg s−1) [47, 48]
• The return of blood perfusion (measured
by the proximal cuff) will be recorded as
the toe systolic pressure [47, 48]
• Toe pressure assessment is repeated for
contralateral side (if appropriate)
• Toe-brachial pressure index value is
calculated by dividing the toe systolic
pressure by the highest (or available)
brachial systolic pressure
• Toe brachial pressure index value
calculated separately for left and right
lower limbs
Note: Brachial systolic pressures obtained in
the ankle-brachial pressure index assessment








• Room temperature (minimum
21–23 ± 1° C) to prevent vasoconstriction
of digital arteries [92]
Ankle-brachial pressure index ≤0.9 will indicate
peripheral arterial disease [44, 45, 53, 54].
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Table 3 Baseline data: arterial assessment (Continued)





• Participants will be rested for a minimum
of 15 min prior to assessment
Ankle-brachial pressure index >1.3 or
non-compressible arteries (i.e. >240 mm Hg)
will indicate arterial calcification [44, 54].
• Participants to avoid use of tobacco and
consumption of coffee for at least one
hour prior to assessment [92, 93]
• Brachial cuff is applied 3 cm above the
cubital fossa
• Brachial pulse located via palpation
• Doppler ultrasound conducting gel is
applied to the skin [92]
• Doppler probe is applied at a 45° angle to
the skin [92], in the direction of the arterial
blood flow
• Cuff is inflated to 20–30 mm Hg beyond the
last audible signal and then slowly deflated
until the audible signal returns [92]
• Repeated for contralateral side (if appropriate)
• Brachial systolic pressure(s) recorded
Note: In the case of an arteriovenous fistula (i.e.
vascular access for haemodialysis treatment)
the brachial systolic pressure will be measured
from the arm free of the fistula [45].
• Ankle cuff is applied 3 cm above the
medial malleolus
• Dorsalis pedis and posterior tibial pulses
are located via palpation
• Doppler ultrasound conducting gel is
applied to the skin [92]
• Doppler probe is applied at a 45° angle to
the skin [92], in the direction of the arterial
blood flow
• Cuff is inflated to 20–30 mm Hg beyond
the last audible signal and then slowly
deflated until the audible signal returns
[92] (maximum 240 mm Hg). Process is
repeated for both the dorsalis pedis and
posterior tibial pulses
• Repeated for contralateral side (if
appropriate).
• The highest of the two systolic pressure
values obtained from the dorsalis pedis and
posterior tibial pulses will be recorded [92]
Note: If the pressure needs to be repeated,
the examiner will wait one minute before
re-inflating the cuff [92].
• Ankle-brachial pressure index value is
calculated by dividing the highest ankle
systolic pressure (i.e. highest value
between dorsalis pedis and posterior tibial
pulses) by the highest (or available)
brachial systolic pressure
Note: Ankle-brachial pressure index value is
calculated separately for left and right lower
limbs.
N/A Not applicable
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Table 4 Baseline data: biomechanical assessment
Biomechanical assessments Equipment Procedure Diagnosis/study definition
Foot deformity The Manchester Scale [57]. • The presence of hammer/claw toes,
hallux abducto valgus, bony
prominences (e.g. prominent metatarsal
heads), Charcot neuroarthropathy and
any other foot deformities (e.g. forefoot
pad atrophy) will be assessed visually [57]
Foot deformity will be recorded
with the presence of ≥1 foot
deformity on either foot.
• Hallux abducto valgus will be graded in
accordance with the Manchester Scale
(no deformity = 1, mild deformity = 2,
moderate deformity = 3, severe
deformity = 4) [57, 58]




Goniometer. • Passive range of dorsiflexion at the 1st
metatarsophalangeal joint will be
measured using goniometry with the
‘static non-weightbearing technique 1’
described by Hopson et al. [60]
Range of motion <65° indicates
limited joint mobility of the first
metatarsophalangeal joint [60].
Plantar pressures Tekscan Matscan® system
(Tekscan Inc, South Boston, MA, USA).
• Plantar pressures will be assessed
during level barefoot walking with the
Tekscan Matscan® system [64, 94]
Mean peak plantar pressures
will be investigated to
determine whether they are
predictive of foot ulceration.
5.7 mm thick floor mat (436 × 369 mm),
2288 resistive sensors (1.4 sensors/cm2),
dynamic events captured with scan
rates of 440 Hz.
• The two-step gait initiation protocol
will be used, with the technique as
described by Zammit et al. [64], except
that both feet will be assessed
FootMat™ 7.0 software (Tekscan Inc,
South Boston, MA, USA).
• The mat will be calibrated for each
patient using that patient’s own weight
before each testing session
• Peak plantar pressure will be measured
at seven regions of the foot, including
the heel, midfoot, first
metatarsophalangeal joint, second
metatarsophalangeal joint, 3–5
metatarsophalangeal joints, hallux and
lesser toes [64]
• The mean peak plantar pressure values
of the three trials of each foot will be
used for final data analysis [64, 95]
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en-Jarrest, France) system was chosen to determine the
toe systolic pressure as it has been shown to be a valid
and reliable clinical assessment tool (Intraclass Correl-
ation Coefficients, ICC = 0.89 and 0.91 for the right and
left sides respectively) [47–49]. The Doppler ultra-
sound technique will be used to assess the ankle and
brachial systolic pressures, as it is known to be a valid
and reliable assessment method in the detection of per-







• The fit (length, width, depth), general features (fixation
flexion point, heel height, materials), style and conditi
will be assessed based on the footwear assessment to
Barton et al. [65]brachial pressure indices ≤0.9 have been reported to
have a high sensitivity (75 %) and specificity (86 %) for
the diagnosis of peripheral arterial disease in pooled
meta-analyses [50].
Peripheral arterial disease will be recorded if any of
the following are present:
 Documentation of known peripheral arterial disease
in the medical records and/or history of lower




Footwear will be deemed inappropriate if there are
any issues with shoe fit, inappropriate style or
condition.




Skin pathology • The presence of hyperkeratosis (callus), heloma dura (corns), uraemic pruritus,
xerosis, calciphylaxis and other skin pathologies will be assessed visually [18, 66,
67, 70–72]
Skin pathology will be recorded with the
presence of ≥1 skin pathology on either foot.
• Severity of xerosis will be graded in accordance with the Xerosis Severity Scale
(mild = 1–2, moderate = 3–4, severe = 5–6) [66, 67]
• Skin pathology will be recorded as ‘present’ or ‘absent’
Nail pathology • The presence of half-and-half nail, absent lunula, onychomycosis, onychocrypto-
sis (ingrown nail), onychauxis (thickened nail) and other nail pathologies will be
assessed visually [70, 71]
Nail pathology will be recorded with the
presence of ≥1 nail pathology on either foot.
• Nail pathology will be recorded as ‘present’ or ‘absent’
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dorsalis pedis and posterior tibial pulses on both
feet [52];
 Toe-brachial pressure index ≤0.6 (either foot)
[44, 45, 53] and/or ankle-brachial pressure index
≤0.9 (either foot/lower extremity) [44, 45, 50, 53, 54].
Arterial calcification will be recorded if any of the fol-
lowing are present:
 Ankle-brachial pressure index >1.3 (either foot/
lower extremity) [44, 54];
 Non-compressible peripheral arteries (i.e. systolic
pressure >240 mm Hg).
Biomechanical assessment
Anomalies of foot structure have been found to be predict-
ive of foot ulceration in prospective studies [41, 55, 56].
The grading of hallux valgus will be evaluated using the
Manchester Scale [57], as it provides a valid representation
of the degree of hallux valgus deformity [58]. Intra- and
inter-rater reliability have been found to be excellent, with
kappa (κ) values of 0.77 and 0.86, respectively [57]. Foot
deformity will be recorded if any of the following are





Foot ulceration • Past or current foot ulcers will be determined by




an• The location, type and duration of a current foot




• Past lower extremity amputations will be determined
by self-report, observation and medical record review
A
pa
or• Lower extremity amputations will be classified as
minor (below ankle) or major (above ankle) Lo
of
A
or Hallux abducto valgus (graded in accordance with
the Manchester Scale) [35, 57];
 Hammer/claw toes [35];
 Bony prominences (e.g. prominent metatarsal
heads);
 Charcot neuroarthropathy [35];
 Other (e.g. forefoot pad atrophy).
Limited joint range of motion (e.g. first metatarsopha-
langeal joint) has also been associated with an increased
risk of foot ulceration in prospective and case–control
studies [55, 56, 59].
Dorsiflexion range of motion of the first metatarso-
phalangeal joint will be assessed in accordance with the
‘static non-weightbearing technique 1’ described by
Hopson et al. [60]. This technique has been shown to
be a reliable clinical measurement (ICC = 0.95). Limited
range of motion at the first metatarsophalangeal joint
will be documented if:
 Passive, non-weightbearing dorsiflexion is <65°
(either foot) [60].
Elevated peak plantar pressures have been found to be a
statistically significant predictor of diabetic foot ulcerationagnosis/study definition
foot ulcer will be defined as a ‘full thickness skin break that is distal
the ankle joint, and may extend into or through the dermis and
olve deeper structures such as bones, tendons, joint capsules
d ligaments’ [41, 55, 73].
lower extremity amputation will be defined as a ‘complete loss of any
rt of the lower extremity [74], including any digit, partial foot amputation
higher’.
wer extremity amputations resulting from trauma or the presence
a tumour will not be recorded.
major amputation will be classified as a loss of limb above the ankle,
minor amputation if below the ankle [74, 75].
Table 8 Baseline data: foot health care behaviours and podiatry attendance
Foot health care behaviours and
podiatry attendance
Procedure Diagnosis/study definition
Foot health care behaviours • Foot health care behaviours will be investigated via
participant interview
Foot health care behaviours will be considered ‘poor’
if the participant answers “no” to ≥3 questions.
• Participants will be asked to respond “yes” or “no” to the
following questions:
(i) Do you inspect your feet daily?
(ii) Do you avoid walking barefoot?
(iii) Are you able to reach your feet?
(iv) Do you treat your own nails and skin lesions?
(v) Have you ever seen a podiatrist before?
Podiatry attendance • Podiatry attendance will be investigated via participant
interview
Podiatry attendance will be recorded as the number
of visits per year.
• Participants will be asked: How many times have you
seen a podiatrist in the last 12 months?
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be assessed during level barefoot walking using a two-step
gait initiation protocol [64] with the Tekscan Matscan®
system (Tekscan Inc, South Boston, MA, USA). Peak
plantar pressures will be measured at seven regions of the
foot, including the heel, midfoot, first metatarsophalangeal
joint, second metatarsophalangeal joint, third to fifth
metatarsophalangeal joints, hallux, and lesser toes [64].
The mean peak plantar pressure values of the three trials
(of each foot) will be used for the purposes of analysis.
Footwear assessment
Minor trauma that results in tissue damage or a break in
the cutaneous barrier of the skin is most commonly due
to ill-fitting or inappropriate footwear, which is frequently
implicated in the development of foot ulcers due to rub-
bing and repetitive trauma [41, 55]. Reiber et al. [55] found
that a minor traumatic event was one of the main compo-
nent causes for the development of foot ulcers, which was
present in 77 % of the foot ulcer pathways. In addition,
pressure from footwear caused the minor traumatic event
in 55 % of the participants [55]. Assessment of footwear
fit, general features, type and condition is based on the
recommendations of the validated footwear assessment
tool described by Barton et al. [65]. Footwear will be
deemed inappropriate if any of the following are present:
 Poor shoe fit (i.e. length, width and depth);
 Inappropriate shoe style (i.e. for foot type, activity,
foot problems etc.) or;
 Poor shoe condition [65].
Dermatological assessment
Skin and nail pathologies have been found to be pre-
dictive of foot ulceration in people with diabetes inprospective studies [27, 55]. The grading of xerosis se-
verity will be evaluated using the Xerosis Severity
Scale, which has been used in several randomised trials
[66–68]. Skin pathology will be recorded if any of the
following are present:
 Hyperkeratosis [16, 69];
 Heloma dura [16, 69];
 Uraemic pruritus [70, 71];
 Xerosis (graded in accordance with the Xerosis
Severity Scale) [67];
 Calciphylaxis [18, 72];
 Other.
Nail pathology will be recorded if any of the following
are present:
 Half-and-half nail [70, 71];
 Absent lunula [70, 71];
 Onychomycosis [27, 69];
 Onychocryptosis [69];
 Onychauxis [69];
 Other.Foot health care behaviours and podiatry attendance
Foot health care behaviours will be considered ‘poor’ if
the participant answers “no” to three or more of the fol-
lowing questions:
 Do you inspect your feet daily?
 Do you avoid walking barefoot?
 Are you able to reach your feet?
 Do you treat your own nails and skin lesions?
(e.g. calluses or corns)
 Have you ever seen a podiatrist before?
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the following question:
 How many times have you seen a podiatrist in the
last 12 months?
Follow-up appointment
The follow-up appointment will occur 12 months after
the baseline appointment. Satellite participants will be
followed-up face-to-face in the dialysis units, whereas
home-therapy participants will be contacted via telephone.
Prior to the follow-up appointment, participant medical
records will be screened for any recent deaths or dis-
charges. This is to ensure that the families of participants
who died during the study are not contacted.
Primary outcome
The primary outcome in this prospective observational
cohort study will be:
 new foot ulcer(s) (including new and reoccurring
ulcers).
A foot ulcer will be defined as a ‘full thickness skin break
that is distal to the ankle joint, and may extend into or
through the dermis and involve deeper structures such as
bones, tendons, joint capsules and ligaments’ [27, 73].
Current foot ulcers (i.e. ulcers present at baseline appoint-
ment) that healed and re-ulcerated during the follow-up
period will also be recorded as new foot ulcers. At the 12-
month follow-up appointment, participants will self-
report whether they developed a new foot ulcer since their
baseline appointment. This information will be verified by
reviewing participants’ medical records. All new foot
ulcers documented at the follow-up appointment will be
differentiated into ‘new’ and ‘reoccurring’ ulcers. All
medical histories of participants will be reviewed to deter-
mine whether any new foot ulcers occurred during the
12-month follow-up period.
Secondary outcomes
Secondary outcome data will also be collected at the
12 month follow-up appointment including:
 number of new foot ulcers;
 time to onset of new foot ulcer(s);
 new lower extremity amputation(s) (including
level of amputation and reason for amputation);
 episodes of infection of the foot or lower extremity
(including type of infection);
 episodes of osteomyelitis;
 foot-related hospitalisations (including reason for
admission, length of stay and foot-related treatments/
procedures received during hospital admission); revascularisation procedure(s) of the lower extremity
(including type of procedure);
 new podiatry interventions (e.g. nail reduction,
prescription of foot orthoses);
 kidney transplantation and;
 mortality (including primary and secondary causes
of death).
All secondary outcomes will be self-reported by par-
ticipants and then verified by reviewing medical re-
cords. All medical histories of participants will be
reviewed to determine whether any of the secondary
outcomes occurred during the 12-month follow-up
period. The time to onset of new foot ulcer(s) will be
defined as the ‘number of days between the baseline
appointment and the development of a new foot
ulcer’. Medical records will be referred to for the first
documented encounter of the new foot ulcer and this
date will be recorded. A lower extremity amputation
will be defined as a ‘complete loss of any part of the
lower extremity [74], including any digit, partial foot
amputation or higher’. Lower extremity amputations
resulting from accidental trauma unrelated to ESRD
or the presence of a tumour will not be recorded.
Lower extremity amputations will be classified as
major or minor. A major amputation will be docu-
mented if there is loss of limb above the ankle, or
minor amputation if below the ankle [74, 75]. Mortal-
ity data will also be collected at the follow-up ap-
pointment. Date of death (including primary and
secondary causes of death) will also be recorded from
reviewing patient medical histories. For those partici-
pants that die during the study period, hospital med-
ical records will be reviewed to assess for the primary
and secondary outcomes up until the date of death.
Sample size
Prospective sample size calculations were performed
using Stata 11 Data Analysis and Statistical Software
(StataCorp LP, Texas, USA) for the following pre-
dictor variables; diabetes mellitus and peripheral
neuropathy. Based on these calculations, a sample of
430 participants will provide 80 % power to detect a
clinically worthwhile difference of 15 % in the inci-
dence of foot ulceration between those with and with-
out diabetes. This sample size will also provide 80 %
power to detect a clinically worthwhile difference of
10 % in the incidence of foot ulceration between
those with and without peripheral neuropathy. This
sample size also allows for a 20 % loss to follow-up.
Data handling and statistical analysis
Data will be entered into a Microsoft Excel® spread sheet
for the development of an analytical file. A predefined
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experienced biostatistician (B.E.) and the research team
prior to commencing the analysis. Baseline sociodemo-
graphic, health-related quality of life and clinical charac-
teristics of participants will be calculated and expressed
as mean ± standard deviation or median (25th to 75th
percentile) for continuous variables and number (pro-
portion) for categorical variables. For comparison of
baseline variables between different groups (for example,
foot ulcer or no foot ulcer), independent samples t-tests
will be calculated for continuous variables and chi-square
(χ2) tests for categorical variables. Unadjusted foot ulcer
incidence rates will be calculated for number of events per
1000 person-years. Multivariate Cox proportional hazards
models will be used to assess predictors of new foot ulcer-
ation and time to event secondary outcomes. Logistic
regression will be used for binary outcomes, such as
prevalence of foot ulcerations.
Base regression models will be developed to fit each
risk factor one at a time with other variables including
baseline demographics and possible confounders as de-
scribed in Table 9 [9, 76, 77], and statistical significance
will be assessed. As a sensitivity analysis, we will also use
forward selection when building models with P-values
set at 0.1. Confounders will be retained if they change
the estimated associations between risk factors and the
outcome by 10 % or more, or are significant at the 5 %
level in adjusted models [78]. After a number of itera-
tions, all risk factors will then be combined in a multi-
variable regression model. Possible interactions will also
be assessed. Strata specific analysis of regression models
using diabetes (yes/no) and sex (male/female) will be
conducted to assess variables for possible effect modifi-
cation. Interaction terms will then be included in the
regression models if there is evidence of an effect modi-
fication from any of these variables. Risk estimates will
be presented as hazard ratios and/or odds ratios (de-
pending on the regression model) with corresponding
95 % confidence intervals (CIs). Statistical significance
will be set at the conventional level of P < 0.05.
Intra-examiner reliability of the assessor (M.R.K.) will
be evaluated using ICCs for continuous data and the
weighted kappa (κ) statistic for ordinal data. To assess
the strength of linear correlation between the two mea-
surements (i.e. to detect random and systematic errors)
[25], ICCs and corresponding 95 % CIs of the type (3, 1)
will be calculated for single measures and type (3, k) for
average measures. ICC values >0.75 indicate good reli-
ability, ICCs ranging from 0.50 to 0.75 imply moderate
reliability and ICCs <0.50 suggest poor reliability [25].
The 95 % Limits of Agreement will also be calculated to
examine the level of agreement between the two measure-
ments [25, 79]. Absolute agreement in addition to linear
weighted kappa will be calculated for ordinal data todetermine the proportion of the total amount of agree-
ment between the two measurements that is not explained
by chance [80, 81]. Weighted kappa values >0.8 represent
excellent agreement, >0.6 substantial levels of agreement,
0.4 to 0.6 moderate agreement and <0.4 poor to fair agree-
ment [25].
Data analysis will be undertaken using IBM SPSS ver-
sion 22.0 or later (IBM Corp, Somers, NY, USA), Stata 11
Data Analysis and Statistical Software (StataCorp LP,
Texas, USA), QualityMetric Health Outcomes™ Scoring
Software 4.5.1 and FootMat™ 7.0 Software (Tekscan Inc,
South Boston, MA, USA).
Discussion
Foot ulceration is a major public health problem that
can have a negative impact on an individual’s general
health, functional status and health-related quality of life
[15–17]. Despite the high prevalence of foot ulceration
in the dialysis population, there is a paucity of high-
quality prospective studies that have investigated the risk
factors associated with this condition. Existing risk factor
studies [5, 6, 8–10, 12, 82–88] have been limited by
small sample sizes, inadequate control for confounding
variables, do not encompass a full range of risk factors,
and the majority are either cross-sectional or retrospect-
ive. Moreover, these study designs do not examine for a
temporal sequence of events, so it is difficult to conclude
whether these risk factors are associated with an in-
crease in foot ulceration. Importantly, our study protocol
has been developed to improve on the design of previous
studies.
Our prospective observational cohort study has been
designed to investigate the risk factors for foot ulcer-
ation in adults with ESRD on dialysis. We have chosen
to evaluate the risk factors for foot ulceration specifically
in dialysis patients, as these individuals have been found
to be at high risk for foot complications [7, 9, 89, 90].
People with or without diabetes will be recruited into
the study. This cohort study will improve on prior stud-
ies by using prospective methods, multi-centre recruit-
ment, statistical methods to control for confounding
variables, and a pre-specified sample size estimation.
The study will investigate participant characteristics,
medical history, blood tests, health-related quality of life
and foot assessment data to assess whether any predict
important clinical outcomes including: new foot ulcer(s),
(primary outcome), number of new foot ulcers, time to
onset of new foot ulcer(s), new lower extremity amputa-
tion(s), episodes of infection of the foot or lower extrem-
ity, episodes of osteomyelitis, foot-related hospitalisations,
revascularisation procedure(s) of the lower extremity, and
mortality (secondary outcomes).
There are several strengths of our study. Firstly, the
baseline data collection form (Additional file 1) is based
Table 9 Risk factors and potential confounding variables
Continuous variables Categorical variables
Participant characteristics Participant characteristics
• Age • Male sex
• Body mass index • Current smoker
Health-related quality of life
(SF-36v2®)
• Living alone
• Physical Component Score
Comorbidities




• Duration of diabetes
• Peripheral neuropathy
Dialysis-related variables
• Peripheral arterial disease







• Ischaemic heart disease
• Total calcium










• Previous foot ulceration
• Peak plantar pressures
• Current foot ulcer present at
baseline
• Previous lower extremity
amputation
Other






• Poor foot health care behaviours
• Regular podiatry attendance
Potential confounding variables that will be considered in the regression
models are boldface
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a comprehensive review of the diabetes literature. Sec-
ondly, one examiner (M.R.K.) will perform all of the
foot assessments on the participants, thus ensuring
consistency and accuracy in the measurements, and re-
ducing the chance of systematic error. Thirdly, we will
assess the reliability of the foot assessment tools.
Twenty participants will be included in a reliability
study, which will evaluate the reproducibility of the
testing procedures. A one week test-retest interval was
chosen as it is sufficient time to avoid fatigue, learning
or memory effects, and will also avoid genuine changes
in the measurement variables [25]. Fourthly, the studyprotocol has been pragmatically designed to encompass
a full range of risk factors and to ensure that the find-
ings can be generalised and applied to clinical practice
(if there are significant risk factors for foot ulceration
identified). Finally, a prospective sample size calculation
was performed to ensure that the study is adequately
powered.
There are also a few potential limitations to our
study. While the examiner will avoid providing feed-
back and education to participants during their foot
assessment, it is not possible to control for all other
potential confounding treatments or interventions that
participants may receive from other sources during
the study period. For example, a participant may re-
ceive an intervention that directly affects their risk of
developing a foot ulcer or not (e.g. prescription of
pressure offloading foot orthoses). In addition, partici-
pants involved in this study may become more aware
of their own foot health as a result of their participa-
tion, and may therefore change their behaviour during
the study period (e.g. start to perform daily foot
checks, seek podiatry treatment, etc.). Ethical consid-
erations may also affect the final outcomes of this
study. For example, the researcher will report any ab-
normal findings from the individual foot assessments
(e.g. new foot ulcer or presence of peripheral arterial
disease) to the medical teams in the dialysis units. As
such, participants may receive new interventions as a
result (e.g. lower extremity revascularisation proced-
ure), which may have a direct effect on the final out-
comes. Lastly, as this cohort is made up of severely
ill participants, mortality and loss to follow-up due to
comorbidities could be potentially higher than the ex-
pected 20 %. If this is exceeded, we will address this
issue by using imputation techniques for missing data
in regression models.
Conclusion
This is the first multi-centre prospective observational
cohort study to investigate risk factors for foot ulcer-
ation in adults with ESRD treated with dialysis. In
addition, we have pre-specified our sample size to ensure
clinically and statistically meaningful results. The study
will improve on prior studies by using prospective
methods, multi-centre recruitment, statistical methods
to control for confounding variables, and a pre-specified
sample size estimation. The results will provide high-
level evidence, and a temporal sequence of events for
risk factors contributing to the development of foot ul-
ceration in the dialysis population. The identification of
potentially modifiable risk factors can inform the design
of future trials investigating the effectiveness of clinical
interventions to reduce the burden of lower limb disease
in adults on dialysis.
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